MIGRAINE & MIGRAINE MANAGEMENT: A REVIEW

Pharma courses

pharma courses



PREVALENCE:
Migraine is neurological disorder that affects 10% of adult population in the United States (18% women and 6% men). Below the age of 12, migraine is common in boys than girls and after puberty (Silberstein, Lipton 2002), prevalence increases 2-3 times in women than men. The questionnaire was returned by 1883 subjects (83.5%). Transformed migraine was diagnosed in 45 (50.6%) of subjects with chronic headache and 2.4% of all subjects (Jestis et al, 1999). The global burden of disease study 2010 (GBD2010) found tension type headache and migraine to be the 2nd and 3rd most prevalent disorders worldwide (Vos et al., 2012).      

CONCLUSION:
Migraine is most common type of primary headache. If diagnosed earlier we can reduce the co- morbidities and enhance the quality of life. Both non-pharmacologic and pharmacologic therapy has a great impact in reducing the migraine attack. Advance in therapy of migraine like SSRI’s, triptans, neuromodulation in acute attack’s reduce the burden on patient. Providing awareness about migraine is essential for good results and great impact in prevention of migraine.

REFERENCES:
1.Alvin Lake, Joseph Rainey, James D Papsdorf. Biofeedback and Rational-Emotive therapy in the management of migraine headache. Journal of Applied Behavior Analysis. 1979; 12:127-140.
2.Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005; 26: 785–93.
3.Andrasik F.behavioural management of migraine headache .biomed pharmacotherapy 1996;50:52-57.
4.Bakal DA, Demejen S, Kaganov JA. Cognitive behavioural treatment of headache. Headache. 1981; 21:81-86.
5.Bartleson JD. Treatment of migraine headache. Mayo Clin Proc. 1999; 74:702-708.
6.Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125–33.
7.Dalessio DJ. Diagnosing the severe headache. Neurology. 1994; 44(3);s6-s12.
8.Deleu D, Hanseens Y. Current and emerging second generation triptans in acute migraine therapy: a comparative review. J Clin Pharmacol. 2000; 40:687-700.
9.Deshmukh SB,Meyer JS:cyclic changes in platelet dynamics and the pathogenesis and prophylaxis of migraine .Headache 17:101-108,1977.
10.Elliott KJ. Taxonomy and Mechanisms of Neuropathic Pain. Semin Neurol. 1994; (14)3:195-205.
11.E.P. Calandre, Jhidalgo J., Garci A Lieva.Trigger point evaluation in migraine patients: an indication of peripheral sensitization linked to migraine predisposition? European Journal of Neurology. 2006; 13:244-249.
12.Evans EW, Lorber KC. Use of 5-HT11 agonists in pregnancy. Ann Pharmacother 2008; 42: 543–49.
13.Fettes I. Migraine in Menopause. Neurology. 1999; 53(1):s29-s33.
14.Ferrari MD. Migraine. Lancet. 1998; 351:1043-1051.
15.Glover V ,Littlewood J ,Sandler M,peatfield R ,et al.why is platelet monoamine oxidase activity low in some headache patients ?in Rose FC (ed) :Advances in migraine research and therapy .New York ,Raven press ,1982 ,pp 127-132.
16.Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine—‘Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008; 28: 383–91. 74
17.Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med 2002; 346: 257–70.
18.Hargreaves  RJ, Shepheard SL. Pathophysiology of migraine-new insights. Can J Neurol Sci. 1999; 26 (l3):S12-S19.
19.Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004; 75: 951–57.
20.Jestis castilo,MD et al.Epidemology of chronic daily headache in the general population.Headache 1999;39,190-t 96.
21.Kakigi R, Nakata H, Inui K, et al. Intracerebral pain processing in a yoga master who claims not to feel pain during meditation. Eur J Pain. 2005;9:581-589.
22.Kim DH, Moon YS, Kim HS, et al. Meditation and yoga reduce emotional stress of chronic pain. Prog NeuropsychopharmacolBiolPsychiatry.2005;29:327331.
23.Krymchantowski AV.acute treatment of migraine .Breaking the paradigm of momotherapy .BMC Neurol 2004; 4:4.DOL 10.1186/1474-2377-4
24.Landy S.Migraine throughout the life cycle .Treatment through the ages .neurology 2004:62(suppl 2):S2-8.
25.Lipton RB, Diamond S, Reed ML, et al. Migraine diagnosis and treatment: results of the American migraine study. Headache. 2001; 41:538-645.
26.Le Doare K, Akerman S, Holland PR, et al. Occipital aff erent activation of second order neurons in the trigeminocervical complex in rat. Neurosci Lett 2006; 403: 73–77 .
27.Matchar DB, Young WB, Rosenberg JA, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks .the USheadache consortium, accessed at www.aan.com/professional/practice /guidelines,2000.
28.Mathew N, Kailasam J, Gentry P, Chernyshev O. Treatment of non responders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache. 2000; 40:464-465.
29.Matharu MS, Bartsch T, Ward N, Frackowiak RSJ, Weiner RL, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 2004; 127: 220–30.
30.Mel R. Respiration. In: A Physiological Handbook for Teachers of Yogasana. Tucson, Arizona: Fenestra Books; 2002;373-382.
31.Olesen J et al, Headache classification committee of the international headache society .the international classification of headache disorders,2nd ed .cephalalgia 2004;24( 1 ):1-151.
32.Olesen J ;Migraine and regional cerebral blood flow ,Trends Neurolsci 8:318-321,1985.
33.Pasero C, Paice JA, McCaffery M. Basic mechanisms underlying the causes and effects of pain. In: McCaffery M, Pasero C, eds. Pain. St. Louis, Mosby, 1999:15–34
34.Peter J Goadsby,Neil H .Raskin. Headache. Harrison’s priniciples of internal medicine, 17th edition.
35.Peter J Goadsby, Till sprenger. Current practice and future directions in the prevention and acute management of migraine. lancet neurol. 2010; 9:285-98.
36.P.J. John et al. Effectiveness of Yoga Therapy in the Treatment of Migraine Without Aura: A Randomized Controlled Trial, (Headache 2007;47:654-661)
37.Pryse-Phillips, Dodick, Edmeads, et al.Guidelines for the nonpharmacologic management of migraine in clinical practice . CMAJ 1998;159:47-54
38.Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine .accessed at www.aan.com/professional/practice /guidelines,2000.
39.Richardson GM, Mcgrath PJ. Cognitive behavioural therapy for migraine headaches :a minial therapist contact approach. Headache. 1989; 29:352-357.
40.Rydzewski W,Wachowicz B:adenosine nucleotides in platelets in and between migraine attacks .in Greene (ed):current concepts in migraine research .New York ,Raven press ,1978,pp 153 -158.
41.Saito A ,Lee TJF .Serotonin as an alternative transmitter in large cerebral arteries of the rabbit .Circ Res 60:220-228,1987.
42.Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population based study. Pain 2003; 106: 81–89
43.Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry. 1960, 23:23-32.
44.Silberstein CGH. Current concepts of migraine and its treatment. Neurologia. 1999; 14:67-77.
45.Silberstein SD. Practice Parameter: Evidence based guidelines for migraine headache (an evidence based review). Neurology. 2000; 55:754-763.
46.Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalagia 2002; 22:491-512.
47.Silberstein SD ,lipton RB,goadsby PJ .Headache in clinical practice.london ,martin Dunitz ,2002:21-33,69-128.
48.Silberstein SD, Goadsby PJ, Lipton RB. Management of migraine: An algorithmic approach. Neurology. 2000; 55(2):S46–52.
49.Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981; 33: 155–88.
50.Sorbi M, Tellegen B. Multimodal migraine treatment. does thermal biofeedback add to the outcomes? Headache. 1984; 24:249-255.
51.Stewartwf, Liptonrb, Celentanodd, et al. Prevalence of migraine headache in the United States, relation to age, income, race and other sociodemographic factors. JAMA. 1992; 267:64-69.
52.Stark S, Spiering E, Mc Neal et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000; 40:513-520.
53.Terry J. Baumann. Pain Management. Pharmacotherapeutics- A Pathophysiologic Approach, 6th Edition, The McGraw-Hill Companies, Inc. United States, 2005; 1089-1104.
54.Tfelt Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60(6):1259-1287.
55.Vos T,Flaxman AD et al .years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010:A systematic analysis for the Global burden of disease study 2010.Lancet.2012;380:2163-2196.
56.www.migraine.org.uk/triggers
57. www.migrainetrust.org
58.www.i-h-s.org /2004.
59.www.hartp.neurology.ucla.edu
60.Warner G, Lance JW. Relaxation therapy in migraine and tension headache. Med J Aust. 1975; 1:298-301.
61.Weitzel KW, Thomas ML, Small RE, Goode JV. Migraine: A comprehensive review of new treatment options. Pharmacotherapy. 1999; 19(8):957-973.
62.Weiner RL, Reed K. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation 1999; 2: 217–21.
63.Wojnar-Horton RE, Hackett LP, Yapp P, Dusci LJ, Paech M, Ilett KF. Distribution and excretion of sumatriptan in human milk. Br J Clin Pharmacol 1996; 41: 217–21.

NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.

SUBMIT YOUR ARTICLE/PROJECT AT editor-in-chief@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email

FIND OUT MORE ARTICLES AT OUR DATABASE

 


 

Pages

FIND MORE ARTICLES